Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4677-4687

  Xue, Mei ^a   Yang, Ming Xing ^a   Zhang, Wei ^a   Li, Xiu Min ^a   Gao, De Hong ^a   Ou, Zhi Min ^a   Li, Zhi Peng ^a   Liu, Su Huan ^a   Li, Xue Jun ^a   Yang, Shu Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Berberine; Hypoglycemic effect; Pharmacokinetic; Solid lipid nanoparticles

Indexed keywords

BERBERINE; GLUCOSE; INSULIN; LABRASOL; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE; TRIPALMITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COPTIS CHINENSIS; DIABETES MELLITUS; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PARTICLE SIZE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE REGENERATION; WEIGHT GAIN; X RAY DIFFRACTION; ZETA POTENTIAL;

MUS; RATTUS;

BERBERINE; HYPOGLYCEMIC EFFECT; PHARMACOKINETIC; SOLID LIPID NANOPARTICLES;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BERBERINE; BODY WEIGHT; EATING; GLUCOSE; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LIPIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84889589387     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51262     Document Type: Article

References (28)

1. Tang J, Feng Y, Tsao S, Curtain R, Wang N. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126:5-17.
2. Yang J, Lin J. Advance on study in anti-tumor mechanism of berberine (Ber). Zhongguo Zhong Yao Za Zhi. 2007;32:881-883. Chinese.
3. Lee KZ. Clinical trials of berberine chloride as pharmaceutical agent of type II diabetes. Hubei J Tradit Chin Med. 2006;28:38-41.
4. Yuan YH. Clinical trial of berberine as pharmaceutical agent of type 2 diabetes. Mod J Integr Tradit Chin West Med. 1999;8:1777-1781.
5. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351.
6. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256-2264.
7. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294:E148-E156.
8. Ko B-S, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005;28:1431-1437.
9. Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One. 2011;6(2):e16556.
10. Lu SS, Yu YL, Zhu HJ, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 2009;200:159-165.
11. Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci. 2009;98:4391-4401.
12. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007;44:931-937.
13. Qu QM, Zhang MF. The pharmacokinetics of berberine. Chin Acad Med Mag Organ. 2002;12:31-35.
14. Liu YT, Hao HP, Xie HG, et al. Extensive intestinal first-pass elimination and predominant hepatic of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38:1779-1784.
15. Paolino D, Cosco D, Cilurzo F, Fresta M. Innovative drug delivery systems for the administration of natural compounds. Curr Bioact Compd. 2007;3:262-277.
16. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81:680-689.
17. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Release. 2003;93:271-282.
18. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105:11613-11618.
19. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1-16.
20. Lu F, Wu SH, Hung Y, Mou CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small. 2009;5: 1408-1413.
21. Chen YX. Nanomedicine Evaluation and Methods. Chemical Industry Press, Beijing: 2012:250-256.
22. Rohit B, Indu PK. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441(1-2):202-212.
23. Li BX, Yang BF, Hao XM, Zhou H, Sun MZ. Study on the pharmacokinetics of berberine in single dosage and coadministration with oryzanol in rabbits and healthy volunteers. Chin Pharm J. 2000;35: 33-35.
24. Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci. 2009;98:4391-4401.
25. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256-2264.
26. Zhang X, Zhao YF, Zhang MH, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat rats. PLoS One. 2012;7:e42529.
27. Lv XY, Li J, Zhang M, et al. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS Pharm Sci Tech. 2010;11:372-382.
28. Kheir MM, Wang YG, Hua L, et al. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol. 2010;48:1105-1110.